InflaRx N.V. (IFRX) News
Follow InflaRx N.V. (IFRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
IFRX - InflaRx to Host Virtual Capital Markets Day
IFRX - InflaRx to Host Virtual Capital Markets Day
NEWS | Sep 21, 2026, 11:30 AM UTC
L
IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement
A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is active, with phase II trials
EQUITY | Sep 09, 2026, 09:16 PM UTC
L
IFRX: INF904 targets ANCA vasculitis with improved safety and efficacy, filling a key market void
A strategic pivot to ANCA vasculitis leverages a validated C5aR1 target and addresses a market gap left by competitor withdrawals. INF904 offers improved pharmacokinetics and safety, with clinical trials set to begin ear
EQUITY | Sep 09, 2026, 09:02 PM UTC
L
IFRX: Advancing a next-gen C5aR1 inhibitor for ANCA vasculitis with phase II trials starting soon
A strategic shift toward ANCA vasculitis is underway, with a new oral C5aR1 inhibitor (INF904) showing improved safety and pharmacokinetics over prior therapies. Multiple clinical programs are advancing, including a phas
EQUITY | Sep 09, 2026, 08:19 PM UTC
L
InflaRx (IFRX) to participate in September investor conferences
InflaRx (IFRX) announces participation in September investor conferences, with no additional details on meetings, filings, or financial guidance in the provided release.
EQUITY | Aug 20, 2026, 11:30 AM UTC
M
InflaRx Files $250 Million Mixed Shelf Offering
InflaRx files mixed shelf offering
EQUITY | Aug 06, 2026, 01:22 PM UTC
L
IFRX - InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
IFRX - InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
EARNINGS | Aug 06, 2026, 11:30 AM UTC
L
IFRX - InflaRx to Report Second Quarter 2026 Results on August 6, 2026
IFRX - InflaRx to Report Second Quarter 2026 Results on August 6, 2026
EARNINGS | Jul 30, 2026, 11:30 AM UTC
L
IFRX Reiterate Outperform, Izicopan first-mover opportunity remains intact @ OPCO
IFRX Reiterate Outperform, Izicopan first-mover opportunity remains intact @ OPCO
EQUITY | Jul 20, 2026, 01:10 PM UTC